The Clorox Company (NYSE: CLX) disinfect your investment portfolio with this Dividend Aristocrat. It is one of the most obvious ways to protect against the outbreak of SARS-CoV-2 is by buying companies that manufacture disinfectants.
Clorox is the leader in this regard due to its namesake bleach. In fact, it kills 99.9% of germs on contact, presumably including the human coronavirus.
So far, the CLX is now experiencing an increase in the demand for its household cleaning products, as the outbreak spreads across the United States. That is the main reason why their shares have been one of the few winners in this volatile market over the past week.
Should You Buy CLX stock now?
Oddly enough, CLX stock has taken a bit of a recent dip because of coronavirus its prospects as a strong generator of passive income. I think the answer is to buy CLX stock is a Yes or Maybe.
Yes, if you are looking to buy a good dividend stock that is currently taking a dip and has the potential of going higher because of the coronavirus. Clorox is also a dividend aristocrat, thanks to his impressive track record of increasing its dividends for 43 consecutive years.
CLX is a Maybe if you are risk-averse and/or unsure about the CLX financial numbers. The disadvantage is that Clorox shares are expensive, with more than 27 times the future earnings. CLX technicals are mostly negative but not as negative as other major stocks.
The bottom line, CLX could be both a coronavirus hedge and a dividend play.
CLX Stock Pivot Points
Pivot Classic Fibonacci Camarilla Woodie DM
S3 134.36 145.59 154.22 140.81 —
S2 145.59 149.88 155.25 145.88 —
S1 151.45 152.52 156.28 152.04 154.13
P 156.81 156.81 156.81 157.11 158.15
R1 162.67 161.10 158.34 163.26 165.35
R2 168.03 163.75 159.37 168.33 —
R3 179.26 168.03 160.40 174.49 —
CLX Wall Street Price Recommendations
Oct-03-19 Reiterated BofA/Merrill Neutral $165 → $160
Sep-23-19 Downgrade Barclays Equal Weight → Underweight $142 → $141
May-20-19 Downgrade Argus Buy → Hold
May-02-19 Upgrade Deutsche Bank Sell → Hold $139
May-02-19 Reiterated BofA/Merrill Neutral $165 → $154
Apr-08-19 Downgrade JP Morgan Neutral → Underweight $159 → $139
Mar-07-19 Initiated Credit Suisse Outperform $172
Dec-06-18 Reiterated BofA/Merrill Neutral $150 → $170
Sep-25-18 Upgrade Argus Hold → Buy
Jul-18-18 Downgrade Goldman Neutral → Sell
Apr-19-18 Downgrade Morgan Stanley Equal-Weight → Underweight
Feb-08-18 Downgrade Argus Buy → Hold
Jan-04-18 Upgrade BofA/Merrill Underperform → Neutral
Dec-14-17 Initiated Deutsche Bank Hold $142
Nov-10-17 Upgrade Consumer Edge Research Neutral → Outperform
Apr-18-17 Initiated Jefferies Hold
Mar-21-17 Initiated JP Morgan Neutral $136
Jan-09-17 Upgrade Barclays Underweight → Equal Weight $115 → $111
Dec-16-16 Upgrade Morgan Stanley Underweight → Equal-Weight
Nov-15-16 Resumed Wells Fargo Market Perform
CLX 1 Day Moving Averages
Name Value Action
Exponential Moving Average (5) 164.78 Sell
Simple Moving Average (5) 166.24 Sell
Exponential Moving Average (10) 165.07 Sell
Simple Moving Average (10) 165.45 Sell
Exponential Moving Average (20) 163.85 Sell
Simple Moving Average (20) 164.47 Sell
Exponential Moving Average (30) 162.32 Sell
Simple Moving Average (30) 162.24 Sell
Exponential Moving Average (50) 159.83 Sell
Simple Moving Average (50) 158.54 Buy
Exponential Moving Average (100) 156.89 Buy
Simple Moving Average (100) 153.71 Buy
Exponential Moving Average (200) 154.95 Buy
Simple Moving Average (200) 154.84 Buy
Ichimoku Cloud Base Line (9, 26, 52, 26) 164.52 Neutral
Volume Weighted Moving Average (20) 164.35 Sell
Hull Moving Average (9) 166.60 Sell
Evidence-based financial writer with 9 years of experience specializing in earnings, economic data coverage, and bond markets. I combine fundamentals, technicals, and macro to identify low-risk, asymmetric opportunities.